Peripheral Artery Disease in Regular Hemodialysis Patients
Egypt120 participantsStarted 2025-07-13
Plain-language summary
Recent studies have reinforced the association between high NLR and PAD in hemodialysis patients. This highlights the need for further studies to confirm its predictive value and determine optimal cut-off thresholds tailored to local patient populations. Accordingly, the present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged ≥18 years.
* Undergoing maintenance hemodialysis for at least 3 months (thrice weekly)
* Able to provide informed consent.
* Willing to undergo clinical and laboratory evaluations, including peripheral vascular assesment
Exclusion Criteria:
* Active infection or sepsis at the time of evaluation
.\* Patients who have a sedimentation rate of more than 60 mm/hour
\*. Known autoimmune or hematologic disorders that may influence leukocyte count.
* Current use of immunosuppressive therapy, corticosteroids, or chemotherapy.5. History of malignancy.6. Patients with incomplete medical records or unable to undergo peripheral vascular assessment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The aim of this study is to evaluate the predictive value of the neutrophil-to- lymphocyte ratio (NLR) for the presence of peripheral artery disease (PAD) in patients undergoing regular hemodialysis.
Timeframe: 6months
2
% of patients with affection in neutrophills to lymphocytes ratio in parient on regular hemodialysis.